DELRAY BEACH, Fla.,
Sept. 2, 2024 /PRNewswire/ -- The
global Non-invasive Prenatal Testing (NIPT) Market is valued at an
estimated USD 7.2 billion in 2024 and
is projected to reach USD 14.1
billion by 2029 at a CAGR of 14.5% during the forecast
period. The global non-invasive prenatal testing (NIPT) market is
driven by rising investments and support from governments and
private sectors, along with a growing preference for non-invasive
methods over traditional invasive techniques due to the safety they
offer for both mother and fetus. Technological advancements,
particularly in next-generation sequencing, have improved the
precision of NIPT, allowing for early detection of chromosomal
abnormalities like trisomy 21. However, the market faces challenges
such as high costs and a lack of skilled professionals, especially
in low-income regions. Despite these barriers, increasing awareness
and continued innovation are expected to drive market growth, with
North America leading due to its
robust healthcare infrastructure. Key players in the market include
Illumina, Natera, Eurofins Scientific, and F. Hoffmann-La Roche,
among others.
![MarketsandMarkets MarketsandMarkets](https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg)
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690
Browse in-depth TOC on "Non-invasive Prenatal Testing
(NIPT) Market"
506 - Tables
63 - Figures
370 -
Pages
Illumina, Inc.: Pioneering Genetic Analysis Solutions
Illumina, Inc. (US) leads the molecular diagnostics space with
integrated systems for analyzing genetic variation and biological
functions. The company offers a comprehensive range of products,
including integrated systems, consumables, and analysis tools,
simplifying genetic research. Its non-invasive prenatal testing
products are part of its core Illyming business. Additionally,
Illumina provides advanced software and cloud-based informatics
platforms for sequencing and array-based systems, catering to
genomic research centers, pharmaceutical companies, hospitals, and
academic institutions. Illumina's global footprint extends across
North America, Europe, Latin
America, the Middle East,
Africa, and Asia Pacific. Key subsidiaries include
BlueGnome, Epic Sciences, and Verinata Health. In 2024, the company
launched DRAGEN v4.3, its next-generation sequencing software, and
in 2023, opened a new office in Bengaluru, India, to strengthen its APAC presence.
Thermo Fisher Scientific, Inc.: Expanding Global Diagnostics
Reach
Thermo Fisher Scientific, Inc. (US) is a global leader in
analytical tools, reagents, and laboratory equipment, serving
diverse sectors such as pharmaceuticals, biotechnology, hospitals,
and research institutions. The company operates across four main
segments: Laboratory Products and Services, Life Sciences
Solutions, Specialty Diagnostics, and Analytical Instruments. Its
Life Sciences and Specialty Diagnostics segments offer sequencing
reagents, PCR instruments, and software solutions. With a presence
in over 150 countries, Thermo
Fisher's global operations span North America, Europe, Latin
America, and Asia. The
company operates under five key brands, including Thermo Scientific
and Invitrogen. In 2023, Thermo
Fisher partnered with Pfizer to expand next-generation
sequencing testing in over 30 countries across Latin America, Africa, the Middle
East, and Asia.
F. Hoffmann-LA Roche AG: Advancing Diagnostics and
Pharmaceuticals
F. Hoffmann-LA Roche AG (Switzerland) is a global pharmaceutical
leader, with its Diagnostics division specializing in molecular
diagnostics and sequencing solutions. Roche provides PCR products
and genome sequencers for hospitals, research institutes, and
clinical labs. With operations in over 100 countries and 29
manufacturing sites globally, Roche serves a wide network across
the US, China, Germany, and more. The company's subsidiaries,
including Chugai Pharmaceutical and Foundation Medicine, enhance
its global reach. In 2021, Roche launched the AVENIO Edge System to
automate next-generation sequencing sample preparation and acquired
TIB Molbiol to strengthen its rapid diagnostic capabilities for
emerging pathogens.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
Product Segment: Products Dominate the NIPT Market
The non-invasive prenatal testing (NIPT) market is segmented by
product and service type into products and services. In 2023, the
product segment held the largest share of the market. This growth
is attributed to the rising demand for advanced, accurate, and
early detection of fetal genetic conditions. Technological
advancements, increased awareness among expectant parents, and the
growing prevalence of chromosomal disorders contribute to this
demand. The non-invasive nature of NIPT, which minimizes risk to
both mother and fetus, further drives its adoption as a preferred
option for prenatal screening, boosting product demand.
Method Segment: Biochemical Screening Tests See Significant
Growth
The NIPT market is divided by method type into ultrasound
detection, biochemical screening tests, and cell-free DNA in
maternal plasma tests. In 2023, the biochemical screening tests
segment held the third-largest market share. Its growth is driven
by affordability, accessibility, and early detection capabilities,
providing essential information about potential chromosomal
abnormalities. Increased awareness and the demand for early,
non-invasive prenatal screening, coupled with advancements in
technology and a rise in chromosomal disorders, contribute to the
expansion of this segment.
Application Segment: Trisomy Leads the NIPT Market
The NIPT market is segmented by application into trisomy,
microdeletion syndrome, and other applications. In 2023, the
trisomy segment accounted for the largest market share. This growth
is driven by rising awareness of trisomy conditions like Down
syndrome and the growing demand for early detection. The
non-invasive nature of NIPT allows for safe, early identification
of trisomy conditions during pregnancy, enabling timely medical
interventions and informed decisions, which supports the expansion
of this segment.
End User Segment: Diagnostic Laboratories Experience Rapid
Growth
The NIPT market is segmented by end user into diagnostic
laboratories, hospitals, and others. In 2023, the diagnostic
laboratories segment experienced the fastest compound annual growth
rate (CAGR). This growth is primarily attributed to strong
connections with healthcare providers, which facilitate sample
collection and quick results. The seamless testing process fosters
trust among doctors and patients, driving the preference for
diagnostic labs and accelerating the growth of this market
segment.
Regional Insights: Europe Holds the Second-Largest Market
Share
The NIPT market is divided by region into North America, Europe, Asia
Pacific, Latin America, and
the Middle East & Africa. In 2023, Europe held the second-largest market share.
This is driven by advancements in medical technology, a high
prevalence of genetic disorders, and a strong healthcare
infrastructure. Robust healthcare systems, increased awareness of
prenatal screening, and favorable reimbursement policies further
support the adoption of NIPT, contributing to the growth and
accessibility of prenatal care in Europe.
For more information, inquire now! Inquire Now
Related Reports:
Single Cell Analysis Market
Digital PCR Market
Preimplantation Genetic Testing Market
NGS Sample Preparation Market
Next Generation Sequencing Market
Get access to the latest updates on Non Invasive Prenatal
Testing Companies and Non Invasive Prenatal Testing Market
Share
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan
Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL
33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/non-invasive-prenatal-testing-nipt-market-worth-14-1-billion-by-2029-driven-by-rising-tech-innovations--marketsandmarkets-302235759.html